Chapter 4 Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-IL 2 receptor antibody versus anti-thymocyte globulin

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Daclizumab

  2012cited by this paper
• Translational Mini‐Review Series on Type 1 Diabetes: Immune‐based therapeutic approaches for type 1 diabetes

  2007cited by this paper
• Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.

  2006cited by this paper
• Genetic, cellular and immune approaches to disease therapy: past and future

  2004cited by this paper
• C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

  2004cited by this paper
• Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials

  2003cited by this paper
• The role of T-cells in the pathogenesis of Type 1 diabetes: From cause to cure

  2003cited by this paper
• Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.

  2002cited by this paper
• Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

  2002cited by this paper
• Autoantibody response to islet transplantation in type 1 diabetes.

  2001cited by this paper
• Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation

  2001cited by this paper
• Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients.

  2001cited by this paper
• Evidence That a Peptide Spanning the B-C Junction of Proinsulin Is an Early Autoantigen Epitope in the Pathogenesis of Type 1 Diabetes1

  2001cited by this paper
• Lessons Learned From More Than 1,000 Pancreas Transplants at a Single Institution

  2001cited by this paper
• Long lasting p53‐specific T cell memory responses in the absence of anti‐p53 antibodies in patients with resected primary colorectal cancer

  2001cited by this paper
• Pancreas Transplantation for Treatment of Diabetes Mellitus

  2001cited by this paper
• Long-term effects of ATG therapy on lymphocyte subsets.

  2001cited by this paper
• Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.

  2000cited by this paper
• Peripheral blood mononuclear cell responses from type 1 diabetic patients and subjects at-risk for type 1 diabetes to human fetal pancreatic tissue proteins.

  2000cited by this paper
• Pancreas transplantation for patients with type 1 diabetes: American Diabetes Association.

  2000cited by this paper
• A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas–kidney transplants

  2000cited by this paper
• Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function

  1999cited by this paper
• Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients.

  1999cited by this paper
• Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failure.

  1999cited by this paper
• Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.

  1999cited by this paper
• Depleting effect of antithymocyte globulin on T-lymphocyte subsets in kidney transplantation.

  1999cited by this paper
• Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.

  1998cited by this paper
• The use of antibodies against the IL-2 receptor in transplantation.

  1998cited by this paper
• Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation.

  1998cited by this paper
• Reduction in HTLV‐I proviral load and spontaneous lymphoproliferation in HTLV‐I–associated myelopathy/tropical spastic paraparesis patients treated with humanized anti‐tac

  1998cited by this paper
• Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies.

  1997cited by this paper
• Progressive Islet Graft Failure Occurs Significantly Earlier in Autoantibody-Positive Than in Autoantibody-Negative IDDM Recipients of Intrahepatic Islet Allografts

  1997cited by this paper
• T-cell reactivity to beta-cell membrane antigens associated with beta-cell destruction in IDDM.

  1995cited by this paper
• COMPARATIVE POLYCLONAL ANTITHYMOCYTE GLOBULIN AND ANTILYMPHOCYTE/ANTILYMPHOBLAST GLOBULIN ANTI‐CD ANTIGEN ANALYSIS BY FLOW CYTOMETRY

  1995cited by this paper
• Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation.

  1993cited by this paper
• Effect of ATG prophylaxis in sensitized and non-sensitized kidney graft recipients.

  1992cited by this paper
• T-cell clones from a type-1 diabetes patient respond to insulin secretory granule proteins

  1990cited by this paper
• Factors associated with early remission of type I diabetes in children treated with cyclosporine.

  1988cited by this paper
• Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases.

  1985cited by this paper

• No citing papers are available for this paper.